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Recent studies suggest that vascular endothelial growth
factor (VEGF) plays a crucial role in the preservation of renal
function and may also serve as a useful biomarker in
monitoring the progression of lupus nephritis (LN). Here we
sought to correlate intrarenal VEGF expression with renal
histopathology and prognosis of LN. Biopsy specimens from
35 patients with Class III or IV LN (ISN/RPS categorization)
were found to have lower levels of intrarenal VEGF than
those found in biopsy tissue taken from 10 donor kidneys
sampled at the time of allograft reperfusion. This reduced
amount of VEGF mRNA in the patients with LN negatively
correlated with glomerular endocapillary proliferation,
crescent formation, and a high histologic activity index but
was positively associated with increased numbers of urinary
podocytes. The level of intrarenal VEGF mRNA accurately
predicted the deterioration of renal function in these patients
within 12 months. Our study shows that expression of VEGF
in renal tissue may serve as a molecular marker of renal
damage and may be a predictive factor for short-term loss of
kidney function in patients with LN.
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Proliferative lupus nephritis (LN) is the most common and
severe histology of LN.1 Steroids and cytotoxic drugs remain
the most commonly used treatments despite the many
associated adverse events.2 Renal histology is essential for the
selection of proper treatment and prognostication of the
disease.3 Specific histological findings, such as crescent
formation, may determine prognosis.3 However, immunosup-
pressive therapy could mitigate such pathology and therefore
improve renal prognosis.4 Since the discovery of the molecular
mechanisms of systemic lupus erythematosus (SLE), novel
immunosuppressive therapies have been introduced.5 Never-
theless, the mechanism of the loss of renal function remains
unknown.6 Studies of intrarenal molecular signatures could
reveal the molecular mechanism of the disease and predict
renal prognosis.7–9 Finally, molecular classification may be
integrated into the histological classification of LN.
The integrity of the glomerular and peritubular capillaries
is vital for renal function. Progressive capillary loss, with
obliteration of the microvasculature, frequently accompanies
fibrosis, which is a characteristic feature of progressive renal
disease.10,11 Progression of glomerulopathy is, at least in part,
due to loss of glomerular integrity. Vascular endothelial
growth factor (VEGF) promotes survival, proliferation, and
differentiation of glomerular endothelial cells.12 Decreased
expression of VEGF has been associated with various
glomerulopathies such as crescentic glomerulonephritis, focal
glomerulosclerosis, IgA nephropathy, pre-eclampsia, and
aging kidneys.10,13,14 Administration of VEGF has been
shown to stabilize kidney function in many models including
the remnant model, thrombotic microangiopathy, and
chronic cyclosporine nephropathy.15–18 The protective
actions were principally mediated through preservation of
glomerular and peritubular capillary structures.18 A recent
study in human diabetic nephropathy has confirmed the role
of VEGF in maintaining renal vasculature and identified it as
a novel biomarker.19 The growing evidence supports the
potential role of VEGF in SLE and nephritis, but the studies
remain inconclusive.13,20–23
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Intrarenal quantitative gene expression may be used
for grading of disease severity.8 For instance, intrarenal
transforming growth factor-b (TGF-b) gene expression could
determine progression of chronic kidney disease.9 In LN, it is
difficult to determine prognosis at the time of renal flare. In
an earlier study, we suggested a serial non-invasive measure-
ment of urinary mRNA for chemokines and growth factors
that could predict the prognosis of this disease.24 In this
study, we aim to determine an association between intra-
renal molecular signatures and renal histology. Furthermore,
we determined whether the molecular signature in the kidney
could predict the progression of LN.
RESULTS
Patients
Fifty-one biopsy samples were obtained during a diagnostic
process of clinically active LN. Ten samples were excluded
due to an inadequate number of glomeruli (less than five) or
chronic scarring glomeruli. Six samples from patients with
LN class V were excluded. Thirty-four samples were from
female patients. Mean (s.e.) age was 31 (1.27) years. The
mean (s.e.) SLE disease activity index (SLEDAI)25 and level of
serum creatinine, 24 h urine protein, and erythrocyturia were
10.58 (0.91), 1.74 (0.26) mg per 100 ml, 3.53 (0.47) g/day,
and 32.70 (15.47) cells per high power field, respectively
(Table 1).
Ten samples of implantation biopsies from donor kidneys
were used as controls. Six kidney samples were from living
donors, and four were from deceased donors (Table 1).
Histological examination of the wedge-biopsies showed
unremarkable findings except for minimal tubular injury.
Renal histology of LN
Eight samples were class III and 27 were class IV by the ISN/
RPS classification of LN, respectively. More details of renal
histology are shown in Table 1. The mean (s.e.) of renal
activity and chronicity indices were 7.49 (0.85) and 4.06
(0.53), respectively. Crescent formation was observed in 12
samples (34%). Other pathologies observed in the samples
were endocapillary proliferation (82%), fibrinoid necrosis
(34%), glomerular neutrophil infiltration (65%), and
thrombotic microangiopathy (16%).
Intrarenal expression of VEGF in LN
The levels of VEGF mRNA in the kidneys of LN patients
(n¼ 35) were decreased as compared with the implantation
biopsies of kidney donors (n¼ 10) (0.64±0.05 vs
0.08±0.13 log copies; Po0.001) (Table 1). The levels of
heme-oxygenase-1 (HO-1) were decreased in LN
(0.45±0.06 vs 0.30±0.26 log copies; P¼ 0.002), whereas
the levels of TGF-b and angiopoeitin-1 (ANGPT-1) were not
different between patients and controls (0.13±0.06 vs
0.03±0.15 log copies; P¼ 0.22 and (0.60±0.08 vs
0.16±0.38 log copies; P¼ 0.44).
Intrarenal VEGF mRNA levels were lower in samples with
crescent formation (0.98±0.03 vs 0.62±0.05 log copies;
Table 1 | Clinical and histological variables at the time of biopsya
Controlsb Patients P-value
Number 10 35
Gender (female/male) 2/8 34/1
Age (years) 33.40±3.76 31.74±1.27 0.74
Clinical parameters
Serum creatinine (mg per 100 ml) 1.18±0.13 1.74±0.26 0.93
Proteinuria (g/day) 0 3.53±0.47 o0.001
Urinary erythrocyte count (per high power) 0 32.70±15.47 o0.001
MDRD-GFR (ml/min per 1.73 m2)c 81.10±9.80 66.36±6.84 0.49
SLEDAId NA 10.58±0.91
Steroid dose (mg/day) 0 32.20±6.64 o0.001
Activity index NA 7.49±0.85
Chronicity index NA 4.06±0.53
Renal histology
III (S), (G) NA 7, 1
IV (S), (G) NA 10, 17
III (A), (A/C) NA 4, 4
IV (A), (A/C) NA 16, 11
Intrarenal mRNA levels
VEGF 0.08±0.13 0.64±0.05 o0.001
HO-1 0.30±0.26 0.45±0.06 0.002
TGF-b 0.03±0.15 0.13±0.06 0.22
Angiopoeitin-1 0.16±0.38 0.60±0.08 0.44
aData are expressed as mean±s.e.
bControl: implantation biopsy from six living donors and four deceased donors.
cMDRD-GFR, glomerular filtration rate at the time of biopsy.
dSLEDAI, Systemic Lupus Erythematosus Disease Activity Index.25
A, active; C, chronic; G, global; HO-1, heme-oxygenase-1; NA, not applicable; S, segmental; TGF-b, transforming growth factor-b; VGEF, vascular endothelial growth factor.
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P¼ 0.04). The biopsy samples with diffuse endocapillary
proliferation (X25% of glomeruli) expressed lower VEGF
levels (0.72±0.05 vs 0.44±0.06 log copies; P¼ 0.003).
Samples with a high activity score (score X3 of total 24)
expressed lower VEGF levels (0.70±0.05 vs 0.40±0.07
log copies; P¼ 0.009). However, samples with glomerular
neutrophil infiltration (X25% of glomeruli) showed no
difference in VEGF levels (0.67±0.08 vs 0.62±0.05 log
copies; P¼ 0.09). Figure 1a–d shows that the presence of
crescent formation, endocapillary proliferation, and a high
activity index were associated with decreased VEGF mRNA
levels.
Correlation between VEGF, TGF-b, AGPT-1, and HO-1
As there is a functional relationship among genes in the
hypoxia-inducible pathway, such as VEGF, TGF-b, AGPT-1,
and HO-1, we attempted to determine the association
between each mRNA level in the biopsy tissues. Figure 2a–c
shows that mRNA levels of VEGF were associated with TGF-
b (R¼ 0.41, P¼ 0.02) and HO-1 (R¼ 0.65, Po0.0001), but
not ANGPT-1 (R¼ 0.15, P¼ 0.41) mRNA levels.
Immunohistochemistry localization of VEGF within renal
biopsies
In kidney donors, the VEGF protein was expressed on
podocytes and markedly expressed on tubular epithelial cells
(Figure 3c and e). In LN, weak VEGF staining was observed
in all samples (Figure 3b, d and f). The VEGF protein was
scarcely seen on glomeruli and tubular epithelial cells of
samples with diffuse endocapillary proliferation (Figure 3b)
or crescent formation (Figure 3d).
Intrarenal VEGF mRNA levels predict a loss of renal function
within 12 months
Active LN patients were treated with standard therapy (see
Materials and Methods) and were followed for 12 months
after kidney biopsy. Of all 35 patients, 10 patients
experienced a loss of their renal function within 12 months
(doubling serum creatinine levels or end-stage renal disease
(ESRD)). We performed receiver operating characteristic
analysis to determine the best cutoff that had the maximal
sensitivity and specificity based on a loss of renal function.
The mRNA cutoff level of 0.63 log copies could predict a
loss of renal function with negative and positive predictive
values of 100 and 53%, respectively. We observed that 53% of
patients with low VEGF mRNA levels, but none of the
patients with high levels, experienced loss of their renal
function within 12 months. Patients with low VEGF mRNA
levels had a significantly increased risk of loss of renal
function, including doubling serum creatinine levels, ESRD,
or both events combined (Po0.001 by log-rank test) (Figure
4a–c). In contrast, crescent formation and a high renal
activity index were not associated with ESRD (data not
shown).
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Figure 1 | Intrarenal vascular endothelial growth factor (VEGF) mRNA and renal pathology. Box and whisker plots show the 10th, 25th,
50th (median), 75th, and 90th percentiles of values (log) for VEGF mRNA levels in the kidney tissue of patients with class III/IV lupus
nephritis. The levels of VEGF mRNA were significantly lower in samples with the presence of crescentic formation (a), endocapillary
proliferation (425% of glomeruli) (b), and high activity index (AI 43) (c), but not glomerular neutrophil infiltration (425% of glomeruli) (d).
(P-value by Mann–Whitney test.) Numbers in the parentheses indicate the number of biopsy samples.
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Urinary loss of podocytes is associated with active LN
In an earlier study, we reported an increase in urinary VEGF
levels in patients with biopsy-proven proliferative LN.24
Although tubular epithelial cells are the main source of VEGF
in the kidney, we hypothesized that the reduction of intra-
renal VEGF in this study may partly be explained by a loss of
podocyte cells into the urine. We therefore analyzed the
relationship between mRNA levels from urine cells and renal
tissue during active LN. To perform a proper comparison,
urine samples were collected from patients (n¼ 21) on the
day of renal biopsy. There was a significant association
between urinary WT-1 (podocyte marker) and VEGF mRNA
levels (Figure 5a) (R¼ 0.51; P¼ 0.02). Urine WT-1 and
VEGF mRNA levels were increased in active LN (urine
WT-1¼ 2.88±0.25 and VEGF¼ 2.14±0.23 log copies). In
contrast, intrarenal WT-1 and VEGF mRNA levels were
decreased in active LN (renal WT-1¼0.56±0.08 and
VEGF¼0.73±0.14 log copies) (Figure 5b).
DISCUSSION
Renal histology study is essential for guidance of patient
management and for predicting prognosis of renal disease.26
Patients with proliferative LN (ISN/RPS class III or IV) are
inevitably destined for chronic or end-stage kidney dis-
ease.27,28 The use of currently available immunosuppressive
treatment has significantly improved renal prognosis.29
However, physicians have been unable to readily predict
individual responses until patients finish a 6-month course of
immunosuppressive treatment.28 In general, a loss of renal
function within 6 months after induction of treatment could
determine long-term prognosis.3 In this retrospective study,
intrarenal VEGF expression was decreased in severe LN.
Moreover, VEGF expression at the time of renal flare may be
a useful predictor of poor renal function within 12 months.
Molecular biomarkers may be useful in the diagnosis and
prognosis of LN in the future.
Several studies have suggested that VEGF plays a key role
in endothelial cell proliferation and capillary repair.16,18,30 In
the model of membranoproliferative GN, blockade of the
VEGF165 protein could lead to progressive renal damage.
31 In
the remnant kidney model, VEGF is reduced in both
glomeruli and tubular cells, which could be corrected by
VEGF replacement.17 VEGF could enhance endothelial cell
repair as well as increase angiogenic response of peritubular
capillaries.32 It is known that VEGF can alter endothelial cell
growth, integrity, and function and may eventually con-
tribute to glomerulopathy.12,18,30 It is expected for reduced
endocapillary proliferation to be associated with decreased
VEGF. This study could not determine such an association.
Vascular endothelial growth factor has been shown to
stabilize kidney function in animal models of thrombotic
microangiopathy16 and chronic cyclosporine nephropathy.17
The protective actions were principally mediated through
preserved glomerular and peritubular capillary structures.18
This may help to preserve glomerular filtration rate by
maintaining glomerular capillary filtration surface area as
well as preventing tubulointerstitial fibrosis.18 This vascular
protective action of VEGF could explain, in this study, an
association between intrarenal VEGF and a loss of renal
function in 12 months. Furthermore, histological evidence in
this study showed expression of VEGF in both the glomeruli
and the tubular cells of kidney donors, whereas there was a
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Figure 2 | Coordinated expression of intrarenal VEGF and related genes. (a) The relationship between the levels of VEGF and TGF-b was
significant at P¼ 0.02 (R¼ 0.41). (b) The relationship between the levels of VEGF and ANGPT-1 was not significant (P¼ 0.41, R¼ 0.15). (c) The
relationship between the levels of VEGF and HO-1 was significant at Po0.0001 (R¼ 0.65).
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marked reduction of VEGF in both structures of kidneys with
active LN.13,33 A study of renal tubular cell lines found that
VEGF acts as a survival factor by induction of cell
proliferation and antiapoptotic responses.34 The expression
of VEGF in renal tubules may result to protect against injury
such as hypoxia, ischemia/reperfusion, hypokalemia, or
oxidative stress.34–36
In this study, intrarenal HO-1 expression was well
correlated with VEGF expression. The mRNA levels of both
genes were decreased in LN as compared with kidney donors.
In human kidney transplantation, both HO-1 and VEGF
mRNA levels have been shown to be decreased in deceased
donors (prolonged ischemia time) as compared with living
donors (short ischemia time).33 In this study, the levels of
VEGF decreased as the severity increased; therefore, further
studies are needed to clarify the role of hypoxic injury in LN.
Studies of serum VEGF in SLE patients have shown higher
levels of VEGF in patients with active SLE than in patients
with inactive SLE or healthy individuals.20–22 It is difficult to
compare VEGF expression among the studies, as the
quantification methods and studied samples (serum versus
tissue) were different.23 The local effects of VEGF may be
different from the systemic responses. The variation of
patients’ characteristics and immunosuppressive treatments
may be considered to be confounding factors. It should be
noted that patients received a moderately high doses of
steroids in this study, although we did not find a relationship
between steroid dose and molecular profiling. Furthermore,
serum VEGF levels may not be associated with intrarenal
VEGF levels, as we may detect VEGF expression from
different cell sources. For instance, the serum VEGF may
originate from vascular endothelial cells, whereas renal VEGF,
Figure 3 | Immunohistochemistry localization of VEGF within renal biopsies of patients with lupus nephritis or kidney donors
(implantation biopsy). (a) Sections were not stained with control monoclonal antibodies. (b) VEGF protein was absent in crescentic
glomeruli of patients with lupus nephritis but markedly expressed in glomeruli of implantation biopsies of kidney donors (c); inset shows
VEGF± podocyte cells (arrows). (d) VEGF was scarcely seen in glomeruli with endocapillary proliferation of lupus nephritis. (e) VEGF was
ubiquitously expressed on tubular epithelial cells of donor kidney tissues but was reduced in the tubulointerstitium of kidneys of patients
with lupus nephritis (f). (Original magnification 400, except inset 600).
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in this study, originates from tubular epithelial cells and
podocytes.34,37 Finally, patients with different stages and
levels of severity of SLE may show different patterns of VEGF
expression.13,22
We previously reported an association between urinary
VEGF expression and active proliferative LN,24 whereas in
this study, an inverse relationship between intrarenal VEGF
and histological activity was found. This has been validated
by performing mRNA studies from same-day collection of
urine and renal tissue. Figure 5 shows an inverse relationship
between urine and intrarenal VEGF mRNA levels. We
hypothesize that there may be a significant urinary podocyte
loss in the active LN.37 Although tubular epithelial cells are
the main source of VEGF in the kidney, urinary podocyte loss
may partly contribute to a reduction of VEGF in crescent
formation.37 Selective knockout of VEGF in the podocyte
showed impaired glomerular capillary formation due to a
loss of endothelial cells, supporting the important role of
VEGF in podocytes in maintaining capillary integrity.38 Yu
et al.39 showed that urinary podocyte loss is associated with
glomerular damage in both primary and secondary glomer-
ulonephritis in mice. We confirmed that there was urinary
podocyte loss in LN by demonstrating an increase in urinary
WT-1 mRNA levels of patients with active nephritis
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(Figure 5). It would be interesting to further determine
whether urinary podocyte numbers might be a functional
biomarker for disease activity.
In conclusion, this study shows the pivotal role of renal
VEGF expression in human LN. Patients with proliferative
LN who had decreased intrarenal VEGF expression are at risk
for a rapid decline of renal function. At the time of renal
flare, the combination of renal pathology such as class III/IV
LN and reduced VEGF expression could predict poor renal
survival. Intrarenal VEGF may become a candidate surrogate
marker for targeting therapy and in development of clinical
trials.
MATERIALS AND METHODS
Patients
A total of 51 patients underwent renal biopsy for diagnostic
evaluation of active LN between 2002 and 2005. All patients
had been diagnosed with SLE according to the 1997 American
College of Rheumatology criteria. All biopsies were examined
by one pathologist (VK) who was not aware of the results of
the molecular study. The samples were classified according to
the histological types of LN using the ISN/RPS classification.40
Six samples from patients with LN class V were excluded from
the study. Ten samples were excluded because of inadequate
number of glomeruli (less than five) or chronic scarring
glomeruli. In class III or IV LN, patients were treated with
oral prednisolone plus a 6-month course of intravenous
cyclophosphamide41 or oral mycophenolate mofetil.42 In
rapidly progressive renal failure from crescentic LN, three
consecutive doses of intravenous methylprednisolone were
given and three sessions of plasmapheresis were performed.
The patients then received oral prednisolone plus a 6-month
course of intravenous cyclophosphamide.43
The control group consisted of kidney samples from
implantation biopsies after reperfusion of kidney allografts.
Inclusion criteria were living or deceased donors with normal
serum creatinine levels and donor age of less than 55 years.
The kidney samples from patients with delayed graft function
or prolonged ischemia time were excluded.
The study was approved by the Ethics Committee for
Human Research of the Faculty of Medicine, Chulalongkorn
University, and written informed consent was obtained from
all patients.
Renal histology
Paraffin sections were stained with hematoxylin and eosin,
periodic acid-Schiff, trichrome, and silver for light micro-
scopy. The specimens were scored for activity and chronicity
indices as described earlier.1 The maximum scores of the
activity index and chronicity index were 24 and 12,
respectively. The activity index was the sum of semiquanti-
tative scores of the following parameters: endocapillary
proliferation, fibrinoid necrosis, cellular crescents, leukocyte
infiltration, hyaline thrombi, and interstitial infiltration.
The chronicity index was the sum of semiquantitative
scores of the following parameters: glomerular sclerosis,
fibrous crescents, interstitial fibrosis, and tubular atrophy.
A percentage of each parameter was calculated by the
equation:
Percentage of each pathology ¼ðNumber of involved glomeruli=
Total number of obtained glomeruliÞ100%
RNA isolation from renal biopsy samples
Diagnostic renal biopsy specimens from LN patients were
obtained and stored at 801C. RNA isolation, quantification,
and reverse transcription into complementary DNA were
performed as described earlier.8
Quantification of mRNA
The mRNA of 18s rRNA, VEGF, ANGPT-1, TGF-b, and
HO-1 were measured using a Light Cycler machine (Roche
Molecular Biochemicals, Indianapolis, IN, USA). The
sequences of primers and fluorescence probes are as follows:
18s rRNA sense, 50-gcccgaagcgtttactttga-30; 18s rRNA anti-
sense, 50-tccattattcctagctgcggtatc-30; 18s rRNA probe, 50FAM-
aaagcaggcccgagccgcc-TAMRA30; VEGF sense, 50-cctacagcacaa
caaatgtgaatg-30; VEGF antisense, 50-caaatgctttctccgctctga-30;
VEGF probe, 50FAM-caagacaagaaaatccctgtgggcct-TAMRA30;
ANGPT-1, sense 50-tgcaaatgtgccctcatgtta-30; ANGPT-1 anti-
sense, 50-tcccgcagtatagaacattcca-30; TGF-b sense, 50-ccctgcccc
tacatttggag-30; TGF-b antisense, 50-ccgggttatgctggttgtaca-30;
TGF-b probe, 50FAM-cacgcagtacagcaaggtcctggcc-TAMRA30;
HO-1 sense, 50-gcccttcagcatcctcagttc-30; HO-1 antisense,
50-ggtttgagacagctgccacat-30; HO-1 probe, 50FAM-tgcagcaga
gcctggaagacaccc-TAMRA30. All primer pairs were designed to
span across an intron–exon boundary to distinguish ampli-
fication of genomic DNA. Each PCR was carried out in a
20 ml reaction volume composed of 2 ml of cDNA template
and 18 ml of a real-time PCR mastermix that contained 10 ml
of 2QuantiTech Probe Mastermix (Qiagen Inc., Chat-
worth, CA, USA), 0.5 mM forward primer, 0.5 mM reverse
primer, and 0.2 mM probe. No fluorescent signal was
generated by these assays when genomic DNA was used as
a substrate, which confirmed that the assays measured only
mRNA. The levels of mRNA were analyzed by a comparative
method.44 The reference RNA was a pool of RNA from
implantation kidney biopsies of live-donors. To control
possible variation among PCR runs, VEGF and an 18s rRNA
plasmid (housekeeping gene) were used as calibrators. The
PCR amplicon for 18s rRNA was used for developing
standard curves. The standard curves were based on the
principle that a plot of the log of the initial target copy of a
standard versus threshold cycles results in a straight line. The
levels of mRNA were expressed as the number of copies per
microgram of total RNA isolated from renal biopsy tissues.
Immunohistochemistry
For immunohistochemistry, tissue samples were fixed in 4%
buffered paraformaldehyde and embedded in paraffin.
Deparaffinized sections were heated in a microwave oven
with sodium citrate buffer. The rabbit anti-VEGF-A antibody
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sc152 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA;
dilution of 1:100) and an Envision reagent kit (Dako,
Carpinteria, CA, USA) were used. The color product of
peroxidase was developed by the 3,5 diaminobenzidine
substrate and counterstaining with hematoxylin. Negative
controls included normal rabbit IgG.
Quantitation of the urine podocyte marker and VEGF
To properly compare intrarenal and urinary gene expression,
a 50 ml urine sample was collected on the day of kidney
biopsy. The urine sample was immediately centrifuged after
collection at 1000 g for 30 min at 41C. Total RNA was isolated
from the cell pellets using an RNA blood mini kit (Qiagen,
Chatworth, CA, USA), measured for concentration, and
reverse transcribed into complementary DNA as described
earlier.24,45 The mRNA levels of VEGF, WT-1 (podocyte
marker), and 18s rRNA (housekeeping gene) were measured
as described above.
Statistical analysis
Statistical analysis was performed using the SPSS software
(version 11.5, SPSS Inc., Chicago, IL, USA). The levels of
mRNA deviated significantly from the normal distribution
(Po0.001) and were reduced by log-transformation. All data
are given as mean and s.e. The Mann–Whitney test was used for
comparison between the two groups. The relationship between
the mRNA levels of each group was estimated with Spearman’s
r correlation. A loss of renal function was determined by a
doubling of serum creatinine calculated from the renal biopsy
date or ESRD. The criteria of ESRD included having a
calculated MDRD-GFR below 15 ml/min or initiation of renal
replacement therapy (dialysis or transplantation). To distin-
guish patients who had a loss of renal function, a receiver
operating characteristic curve of mRNA levels was used to
determine the cutoff levels that maximized the combined
sensitivity and specificity. We estimated the probabilities of a
loss of renal function using the Kaplan–Meier method and
compared them using a log-rank test. All P-values below 0.05
were considered statistically significant.
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